2. Peptides
  3. Peptide and Derivatives
  4. Cell-adhesion Peptides

Cell-adhesion Peptides

Custom Peptide Synthesis

Cell-adhesion peptides mimic adhesive motifs derived from extracellular matrix proteins and regulate cellular adhesion, migration, proliferation, and differentiation by binding to cell surface receptors such as integrins. They are widely applied in biomaterial modifications and drug delivery systems.

Cell-adhesion Peptides (84):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P0023
    Cyclo(-RGDfK) 161552-03-0 99.48%
    Cyclo(-RGDfK) is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM. Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface.
    Cyclo(-RGDfK)
  • HY-P0278
    RGD 99896-85-2 99.12%
    RGD is a tripeptide that effectively triggers cell adhesion, addresses certain cell lines and elicits specific cell responses; binds to integrins.
    RGD
  • HY-P1740
    RGD peptide (GRGDNP) 114681-65-1 99.83%
    RGD peptide (GRGDNP) is an inhibitor of integrin-ligand interactions. RGD peptide (GRGDNP) competitively inhibits α5β1 binding with extracellular matrice (ECM). RGD peptide (GRGDNP) promotes apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing. RGD peptide (GRGDNP) plays an important role in cell adhesion, migration, growth, and differentiation.
    RGD peptide (GRGDNP)
  • HY-P2300
    Cyclo(Arg-Gly-Asp-D-Phe-Cys) 862772-11-0 98.73%
    Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC), a cyclic RGD peptide which has high affinity to αvβ3, can disrupt cell integrin interactions. Cyclo(Arg-Gly-Asp-D-Phe-Cys) inhibits pluripotent marker expression in embryonic stem cells (ESCs) and the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) can be used in the research of tumors.
    Cyclo(Arg-Gly-Asp-D-Phe-Cys)
  • HY-12290
    Arg-Gly-Asp-Ser 91037-65-9 99.93%
    Arg-Gly-Asp-Ser is an integrin binding sequence that inhibits integrin receptor function. Arg-Gly-Asp-Ser directly and specifically bind pro-caspase-8, pro-caspase-9 and pro-caspase-3, while it does not bind pro-caspase-1.
    Arg-Gly-Asp-Ser
  • HY-P10918
    F11R peptide TFA
    F11R peptide TFA is a F11 receptor molecule. F11R peptide TFA inhibits anti-F11R antibody-induced platelet aggregation, and inhibits the adhesion of platelets to cytokine (TNFα and INF-γ)-inflammed endothelial cells. F11R peptide TFA can be used for research of atherosclerotic plaques and associated thrombotic disease.
    F11R peptide TFA
  • HY-P4794A
    Osteoblast-Adhesive Peptide acetate
    Osteoblast-Adhesive Peptide (Lys-Arg-Ser-Arg) acetate is an adhesion peptide that can be used as a dental/orthopedic biomaterial to support and enhance osteoblast (anchorage-dependent cell) adhesion. Osteoblasts adhere via both integrin-mediated and proteoglycan-mediated mechanisms. Osteoblast-Adhesive Peptide acetate may be osteoblast- or osteocyte-specific and participate in proteoglycan-mediated osteoblast adhesion.
    Osteoblast-Adhesive Peptide acetate
  • HY-P5363A
    PAP 248-286 acetate
    PAP 248-286 (Prostatic acid phosphatase (248-286)) acetate is a biological active peptide. PAP (248-286) acetate is a semen-derived enhancer of viral infection (SEVI) factor found in semen. This peptide greatly increases HIV infection through enhanced virion attachment to target cells..
    PAP 248-286 acetate
  • HY-P0122
    iRGD peptide 1392278-76-0 98.79%
    iRGD peptide is a 9-amino acid cyclic peptide, triggers tissue penetration of agents by first binding to αv-integrins, then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties.
    iRGD peptide
  • HY-P0290
    GRGDSP 91037-75-1 99.91%
    GRGDSP, a synthetic linear RGD peptide, is an integrin inhibitor.
    GRGDSP
  • HY-P0131A
    Laminin peptide CDPGYIGSR TFA 2828432-44-4 99.75%
    Laminin peptide CDPGYIGSR (Laminin (925-933)) TFA is a peptide derived from the Laminin B1 chain that binds to the laminin receptor.
    Laminin peptide CDPGYIGSR TFA
  • HY-P1740A
    RGD peptide (GRGDNP) (TFA) 99.94%
    RGD peptide (GRGDNP) TFA is an inhibitor of integrin-ligand interactions. RGD peptide (GRGDNP) TFA competitively inhibits α5β1 binding with extracellular matrice (ECM). RGD peptide (GRGDNP) TFA promotes apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing. RGD peptide (GRGDNP) TFA plays an important role in cell adhesion, migration, growth, and differentiation.
    RGD peptide (GRGDNP) (TFA)
  • HY-P4322
    H-Ile-Lys-Val-Ala-Val-OH 131167-89-0 99.42%
    H-Ile-Lys-Val-Ala-Val-OH is one of the most potent active sites of laminin-1. H-Ile-Lys-Val-Ala-Val-OH promotes cell adhesion, neurite outgrowth, and tumor growth. H-Ile-Lys-Val-Ala-Val-OH stimulates BMMSC population growth and proliferation by activating MAPK/ERK1/2 and PI3K/Akt signalling pathways.
    H-Ile-Lys-Val-Ala-Val-OH
  • HY-126437B
    Poly-L-lysine hydrobromide (MW 70000-150000) 25988-63-0
    Poly-L-lysine (hydrobromide) (MW 70000-150000), a positively charged amino acid polymer, is a nonspecific attachment factor for cells. Poly-L-lysine (hydrobromide) (MW 70000-150000) has good biocompatibility. Poly-L-lysine (hydrobromide) (MW 70000-150000) is used to increase cell adhesion to solid substrates by enhancing electrostatic interaction between negatively charged ions of the cell membrane and the culture surface.
    Poly-L-lysine hydrobromide (MW 70000-150000)
  • HY-P1408A
    Obtustatin triacetate 99.90%
    Obtustatin triacetate is a 41-residue non-RGD disintegrin. Obtustatin triacetate can be isolated from the venom of Vipera lebetina obtusa. Obtustatin triacetate is a potent and selective inhibitor of integrin α1β1 adhesion to type IV collagen. Obtustatin triacetate inhibits angiogenesis and may be used in cancer research.
    Obtustatin triacetate
  • HY-P0023A
    Cyclo(-RGDfK) TFA 500577-51-5 99.82%
    Cyclo(-RGDfK) TFA is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM. Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface.
    Cyclo(-RGDfK) TFA
  • HY-P0322
    GRGDSPK 111119-28-9 98.12%
    GRGDSPK (EMD 56574) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK (EMD 56574) is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK is used to study the role of integrins in bone formation and resorption.
    GRGDSPK
  • HY-P0278A
    RGD Trifluoroacetate 2378808-45-6 99.55%
    RGD Trifluoroacetate is a tripeptide that effectively triggers cell adhesion, addresses certain cell lines and elicits specific cell responses; RGD Trifluoroacetate binds to integrins.
    RGD Trifluoroacetate
  • HY-P0122B
    iRGD peptide 1 TFA 98.45%
    iRGD peptide 1 TFA is the prototypic tumor-specific tissue-penetrating peptide, which delivers agents deep into extravascular tumor tissue. iRGD peptide 1 TFA has anti-metastatic activity.
    iRGD peptide 1 TFA
  • HY-P0295
    Gly-Arg-Gly-Asp-Ser 96426-21-0 99.91%
    Gly-Arg-Gly-Asp-Ser (GRGDS) is a pentapeptide that forms the cell-binding domain of a glycoprotein, osteopontin. Gly-Arg-Gly-Asp-Ser binds to integrin receptors αvβ3 and αvβ5 with estimated IC50 of ～5 and ～6.5 μM
    Gly-Arg-Gly-Asp-Ser